Clinical Next-Generation Sequencing Market, by Technology (Whole Exome Sequencing (WES), Whole Genome Sequencing (WGS), Targeted DNA Sequencing, Targeted RNA Sequencing, Single Cell Sequencing, Synthetic Long Read Sequencing, Metagenomics, Transcriptomics) and, by End-User (Hospitals and Diagnostic Centers, Academic and Research Institutes, Biotechnology and Pharmaceutical Companies): Opportunity Analysis and Industry Forecast, 2023-2032

The Clinical next-generation sequencing market study provides a detailed analysis pertaining to the global market size & forecast, segmental splits, and further bifurcation into regional & country-level. In addition, it outlines the market dynamics & trends, Porters’ five force analysis, competitive landscape, and market share analysis.

Clinical next-generation sequencing market Revenue ($Million), By Application, 2023 to 2032

Graph for representation purpose only

Segmental Outlook

The global Clinical next-generation sequencing market is segmented into by technology, by end-user.

The segmental analysis includes real time and forecast in both quantitative and qualitative terms. This will assist clients to recognize the most lucrative segments for investors to capitalize in the market, based on a comprehensive backend analysis regarding the segmental performance, along with brief understanding of the operating companies in the market and their development activities in line with their products.

Clinical next-generation sequencing market Revenue ($Million), By Type, 2023 to 2032

Graph for representation purpose only

Competitive Scenario

The report profiles the top players operating across the globe, along with market share analysis, and an outlook on top player positioning. In addition, the study focuses on the developmental strategies such as product launch, mergers & acquisitions, and collaborations adopted by the market frontrunners to maintain a competitive edge in the marketspace.

Key companies identified in the report are Roche Diagnostics, Thermo Fisher Scientific, Illumina Inc., Qiagen N.V., Agilent Technologies Inc., Pacific Biosciences, 10x Genomics Inc., BIO-RAD Laboratories Inc., Macrogen Inc., Eurofins Scientific SE

Report Coverage

• Market Size Projections: 2023 to 2032

• Major Segments Covered: by technology, by end-user

• Market Dynamics and Trends

• Competitive Landscape Reporting

Note

• Apart from the list of countries and companies provided in the study, clients have the liberty to customize the list according to their stated requirements.

• Given that AMR offers 20% free customization policy, clients can request AMR for a tailor-made report by considering their requirements. However, any kind of modification will be finalized post a quick feasibility check.

  Clinical Next-Generation Sequencing Market, by Technology Report Highlights

Aspects	Details
By Technology	Whole Exome Sequencing (WES) Whole Genome Sequencing (WGS) Targeted DNA Sequencing Targeted RNA Sequencing Single Cell Sequencing Synthetic Long Read Sequencing Metagenomics Transcriptomics
By End-User	Hospitals and Diagnostic Centers Academic and Research Institutes Biotechnology and Pharmaceutical Companies
By Region	North America  (U.S., Canada, Mexico) Europe  (France, Germany, Italy, Spain, UK, Russia, Rest of Europe) Asia-Pacific  (China, Japan, India, South Korea, Australia, Thailand, Malaysia, Indonesia, Rest of Asia-Pacific) LAMEA  (Brazil, South Africa, Saudi Arabia, UAE, Argentina, Rest of LAMEA)
Key Market Players	Macrogen Inc., Qiagen N.V., Roche Diagnostics, Illumina Inc., BIO-RAD Laboratories Inc., Pacific Biosciences, Agilent Technologies Inc., Eurofins Scientific SE, 10x Genomics Inc., Thermo Fisher Scientific Inc.

^*Terms and Conditions Apply